474 related articles for article (PubMed ID: 31246976)
21. Sex differences in the effect of HbA1c-defined diabetes on a wide range of cardiovascular disease risk factors.
Du T; Yuan G; Zhou X; Sun X
Ann Med; 2016; 48(1-2):34-41. PubMed ID: 26758477
[TBL] [Abstract][Full Text] [Related]
22. Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.
Kimak E; Hałabiś M; Baranowicz-Gąszczyk I; Solski J; Książek A
J Zhejiang Univ Sci B; 2011 May; 12(5):365-71. PubMed ID: 21528490
[TBL] [Abstract][Full Text] [Related]
23. Lipid modification in type 2 diabetes: the role of LDL and HDL.
Vergès B
Fundam Clin Pharmacol; 2009 Dec; 23(6):681-5. PubMed ID: 19650852
[TBL] [Abstract][Full Text] [Related]
24. Atherogenic lipid phenotype in a general group of subjects.
Van J; Pan J; Charles MA; Krauss R; Wong N; Wu X
Arch Pathol Lab Med; 2007 Nov; 131(11):1679-85. PubMed ID: 17979486
[TBL] [Abstract][Full Text] [Related]
25. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
26. [Dyslipidemia and atherosclerosis].
Koba S; Hirano T
Nihon Rinsho; 2011 Jan; 69(1):138-43. PubMed ID: 21226274
[TBL] [Abstract][Full Text] [Related]
27. Advanced lipoprotein profile identifies atherosclerosis better than conventional lipids in type 1 diabetes at high cardiovascular risk.
Serés-Noriega T; Ortega E; Giménez M; Perea V; Boswell L; Mariaca K; Font C; Mesa A; Viñals C; Blanco J; Vinagre I; Pané A; Esmatjes E; Conget I; Amor AJ
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1235-1244. PubMed ID: 37088651
[TBL] [Abstract][Full Text] [Related]
28. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
Rizzo M; Berneis K
J Atheroscler Thromb; 2005; 12(5):237-9. PubMed ID: 16205019
[TBL] [Abstract][Full Text] [Related]
29. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
30. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
31. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.
Rizzo M; Spinas GA; Cesur M; Ozbalkan Z; Rini GB; Berneis K
Atherosclerosis; 2009 Dec; 207(2):502-6. PubMed ID: 19643412
[TBL] [Abstract][Full Text] [Related]
32. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
[TBL] [Abstract][Full Text] [Related]
33. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
34. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
36. Is Lipid Accumulation Product Associated with an Atherogenic Lipoprotein Profile in Brazilian Subjects?
Cartolano FC; Pappiani C; Freitas MCP; Figueiredo Neto AM; Carioca AAF; Damasceno NRT
Arq Bras Cardiol; 2018 Apr; 110(4):339-347. PubMed ID: 29791572
[TBL] [Abstract][Full Text] [Related]
37. Plasma Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Concentration Ratio and Early Marker of Carotid Artery Atherosclerosis.
Nimkuntod P; Tongdee P
J Med Assoc Thai; 2015 May; 98 Suppl 4():S58-63. PubMed ID: 26201135
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular disease and dyslipidemia: beyond LDL.
Pöss J; Custodis F; Werner C; Weingärtner O; Böhm M; Laufs U
Curr Pharm Des; 2011; 17(9):861-70. PubMed ID: 21418031
[TBL] [Abstract][Full Text] [Related]
39. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
40. Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9.
Quispe R; Al-Hijji M; Swiger KJ; Martin SS; Elshazly MB; Blaha MJ; Joshi PH; Blumenthal RS; Sniderman AD; Toth PP; Jones SR
J Clin Lipidol; 2015; 9(4):511-8.e1-5. PubMed ID: 26228668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
